Cancer Immunotherapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies and Cancer Vaccines) By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others) By Operation (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By End User (Hospitals & Clinics, Cancer Research Centers, Others) and Region Forecast 2020-2031

Cancer Immunotherapy Market size was valued at US$ 252.13 billion in 2024 and is expected to reach US$ 553.91 billion by 2031, growing at a significant CAGR of 11.9% from 2025-2031. The market is all about therapies meant to exploit the body's immune system in cancer cell detection and combat. The market is driven by advances in biotechnology, rising cancer incidence rates, and growing investment in immunotherapy. The development of bioinformatics technologies is making drug discovery faster with more targeted and efficient treatments. The high rate of cancer incidence across the globe is driving the demand for immunotherapies, and regulatory approval is making breakthrough therapy approvals faster.

Further, combination therapies and personalized therapies are expanding the range of treatment and enhancing outcomes. The market is still restricted by factors like expensive treatments, which restrict accessibility, mainly in economically lesser developed areas. Excessive regulatory demands and lengthy approval rates complicate commercialization. Patient response heterogeneity remains an issue, with the majority of the treatment being unevenly effective. Moreover, competition from alternative cancer therapies and long-term safety and resistance issues are challenges for market development.

Facts & Figures

• In 2025, 2,041,910 new cases of cancer will be diagnosed in the United States, and 618,120 will die from cancer.
• Prostate, lung, and colorectal cancers are estimated 48% of all cancers in men in 2025. The three most frequent cancers in women include breast, lung, and colorectal, and they will have an estimated 51% of all new cancer diagnoses in women in 2025.
• The incidence rate of new cancer cases (cancer incidence) is 445.8 per 100,000 men and women per year (based on 2018–2022 cases).
• The rate of cancer deaths (cancer mortality) is 145.4 per 100,000 men and women annually (based on 2019–2023 fatalities).
• Men have a higher cancer mortality rate than women (171.5 per 100,000 men and 126.3 per 100,000 women). Cancer mortality, when comparing sex and race/ethnicity groups, is highest for non-Hispanic Black men (203.6 per 100,000) and lowest for non-Hispanic Asian/Pacific Islander women (83.1 per 100,000).

Key Developments:

• In January 2025, AbbVie and Simcere Zaiming joined hands for co-development of new trispecific antibody candidate to treat multiple myeloma.
• In December 2024, AstraZeneca's immunotherapy drug Imfinzi (durvalumab) became the first and only approved regimen to treat adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease had not progressed after platinum-based chemotherapy and radiation therapy.
• In November 2024, Dr. Reddy's Laboratories launched Zytrovi, an immunotherapy drug for metastatic nasopharyngeal carcinoma (NPC) therapy.
• In September 2024, The FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor, a critical breakthrough in cancer immunotherapy. This drug gives patients a faster route of treatment (7 minutes versus 30-60 minutes of intravenous infusion) without losing safety and efficacy over the intravenous version.

Cancer Immunotherapy Market Segmentation:

Based on the vaccine type:

• Monoclonal Antibodies
• Immunomodulators
• Oncolytic Viral Therapies and Cancer Vaccines

Monoclonal antibodies segment was leading in the market and accounted for the highest revenue share. Increased investment in R&D of monoclonal antibodies-like bispecific antibodies, conjugated monoclonal antibodies, and naked antigen binding antibodies-has opened new avenues for growth opportunity for firms operating in the oncology therapeutics market. The next-generation monoclonal antibodies are designed to transmit or possess adaptive immunity, antibody dependent cellular toxicity, and antigen specificity. Monoclonal antibodies are being vastly studied for their therapeutic effects on various types of cancer.

Based on the application:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head and Neck Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Others

Lung cancer segment recorded the highest share in terms of revenue. the rising incidence of lung cancers, heightened awareness programs, rising acceptance of immunotherapies, and availability of a strong pipeline of candidates under investigation are some of the major drivers anticipated to propel the segment's growth. Additionally, mounting product approvals and product launches are spurring demand ahead.

Based on the end use:

• Hospitals & Clinics
• Cancer Research Centers
• Others

Hospitals & Clinics segment generated the highest revenue share. Apart from increased incidence of diseases, augmented treatment rate, greater awareness and malignancy diagnosis and a considerable number of hospitals providing immunotherapies is helping to fuel growth in the number of patients being treated. Hospitals are using immunotherapies in order to treat cancer. According to the National Cancer Institute article that came out in April 2023, in the United States 25% of patients passed away in a hospital and 62% were hospitalized at least once during the past month of life for the cancer therapies.

Based on the distribution channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hospital pharmacy segment was the market leader. The growing demand for hospital immunotherapies and the growing rate of hospitalization due to a rise in cancer diseases propel hospital pharmacy growth. The complexity of the treatment and people getting infected aged above 65 years raised the rate of hospitalization of cancer patients. This has led to a large portion of the segment. Consequently, the share of this segment in this market is huge.